



Robust Plinabulin Pipeline: 2 Near-Term NDAs & I/O Clinical Trials



	Indication / Target	Program	Trial Name / Collaborator	Preclinical	Phase 1	Phase 2	Phase 3	Commercial Rights ¹
Late stage	NSCLC (2 nd /3 rd line)	Plinabulin + docetaxel	DUBLIN-3	Ph. 3 primary and secondary endpoints presented at ESMO '21				Global
	CIN	Plinabulin + pegfilgrastim	PROTECTIVE-1 & PROTECTIVE-2	Ph. 3 primary endpoint met Nov. '20				Global
Triple Combo IO (IT)	SCLC	Plinabulin + nivolumab + ipilimumab	US sites, including Rutgers University as lead site					Global
	7 cancers (PD-1/PD-L1 failed)	Plinabulin + PD-1/PD-L1 + radiation/chemo	THE UNIVERSITY OF TEXAS MD Anderson Cancer Center					Global
Investigator-initiated IO	Oral T cell co-stimulator	BPI-002						Global
	IKK inhibitor	BPI-003						Global
	Oral neo-antigen generator	BPI-004						Global
SEED Therapeutics	KRAS and additional targets	Targeted Protein Degradation (TPD, molecule glue platform)						Global
	Multiple							Global